𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies

✍ Scribed by Rob C. Roovers; Toon Laeremans; Lieven Huang; Severine De Taeye; Arie J. Verkleij; Hilde Revets; Hans J. de Haard; Paul M. P. van Bergen en Henegouwen

Book ID
105967103
Publisher
Springer-Verlag
Year
2006
Tongue
English
Weight
542 KB
Volume
56
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Targeting of cells expressing wild-type
Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: A two-pronged attack for tumour therapy
✍ Helmout Modjtahedi; David K. Moscatello; Gary Box; Margaret Green; Christine Sho πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 539 KB

## Abstract With a view to their use in cancer therapy, we have produced rat monoclonal antibodies (MAbs) directed against 5 distinct epitopes (A–E) on the external domain of the wild‐type human EGF receptor (EGFR). Here, we have investigated the relative binding and anti‐tumour activity of our ant

Anti-EGFR monoclonal antibodies which ac
Anti-EGFR monoclonal antibodies which act as EGF, TGFΞ±, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours
✍ Helmout Modjtahedi; Toshi Komurasaki; Hitoshi Toyoda; Christopher Dean πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 French βš– 294 KB

Epiregulin is the newest member of the epidermal growth factor (EGF) family of ligands that was isolated from conditioned medium of the murine fibroblast-derived tumour cell line NIH3T3/T7. Here, using a panel of anti-EGFR receptor (EGFR) monoclonal antibodies (MAbs) directed against 4 distinct epit